AKBA vs LXRX
AKBA: A biopharmaceutical company specialized in kidney disease therapeutics with a commercial portfolio for anemia and mineral metabolism and a pipeline of rare disease assets. LXRX: An early-stage commercial biopharmaceutical company with a gene-discovery platform advancing cardiovascular and metabolic therapies, headlined by commercialized INPEFA and Phase 3 hypertrophic cardiomyopathy candidate sotagliflozin.
Side-by-side fundamentals
| Metric | AKBA | LXRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.26 | $2.25 | |
| Market cap as of 2026-07-23 | $349M | $1.0B | |
| Net margin as of 2026-07-23 | -8.8% | -37.5% | AKBA higher |
| Gross margin as of 2026-07-23 | +79.3% | +99.5% | LXRX higher |
| Operating margin as of 2026-07-23 | +2.3% | -34.8% | AKBA higher |
| ROE as of 2026-07-23 | -62.7% | -18.6% | LXRX higher |
| ROA as of 2026-07-23 | -5.7% | -11.8% | AKBA higher |
| Debt / equity as of 2026-07-23 | 7.09 | 0.24 | LXRX lower |
| Revenue growth (YoY) as of 2026-07-23 | +25.7% | +123.1% | LXRX higher |
| Revenue CAGR (3y) SEC XBRL | -6.9% | +610.3% | LXRX higher |
| Beta as of 2026-07-23 | 0.26 | 1.03 | |
| 1-year return as of 2026-07-22 close | -67.3% | +87.5% | LXRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.